Reata Pharmaceuticals Secures $78,000,000 New Round

  • Feed Type
  • Date
  • Company Name
    Reata Pharmaceuticals
  • Mailing Address
    2801 Gateway Drive Irving, TX 75063
  • Company Description
    Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel treatments for cancer, inflammation, and neurodegenerative diseases.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    This financing will fund the second of two pivotal trials of Reata’s lead product candidate, bardoxolone methyl (bardoxolone), in patients with advanced chronic kidney disease (CKD) and Type 2 diabetes.
  • M&A Terms
  • Venture Investor
  • Venture Investor
    Novo Ventures